These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3348523)

  • 1. [Peroperative circulatory arrest after intravenous injection of erythromycin lactobionate].
    Hummel JC; Haberer JP
    Ann Fr Anesth Reanim; 1988; 7(1):85-6. PubMed ID: 3348523
    [No Abstract]   [Full Text] [Related]  

  • 2. [Jet intravenous injection of erythromycin lactobionate. A possible cause of the occurrence of crisis in torsade de pointe].
    Camilleri JF; Deharo JC; Panagidès D; Broin P; Mésana T; Blin D; Mouly-Bandini A; Dubouloz C; Goudard A; Montiès JR
    Ann Cardiol Angeiol (Paris); 1989 Dec; 38(10):657-9. PubMed ID: 2698118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Attack of torsades de pointes induced by an intravenous injection of erythromycin lactobionate].
    Kilani F; Marsepoil T
    Ann Fr Anesth Reanim; 1988; 7(3):270-1. PubMed ID: 3408043
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cardiotoxicity of intravenous erythromycin lactobionate in the neonatal period].
    Gouyon JB; Betremieux T; Petion AM; Beneton C; Bavoux F
    Arch Fr Pediatr; 1991 May; 48(5):375-6. PubMed ID: 1859247
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate.
    Karmody CS; Weinstein L
    Ann Otol Rhinol Laryngol; 1977; 86(1 Pt 1):9-11. PubMed ID: 835977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of erythromycin lactobionate to facilitate the postpyloric passage of tubes in children.
    Gouyon JB
    J Pediatr Gastroenterol Nutr; 1992 Jan; 14(1):120. PubMed ID: 1573505
    [No Abstract]   [Full Text] [Related]  

  • 7. [Electrophysiological study of pro-arrhythmogenic effects of erythromycin].
    Ponsonnaille J; Citron B; Richard A; Trolese JF; Chaperon A; Barret B; Gras H
    Arch Mal Coeur Vaiss; 1988 Aug; 81(8):1001-8. PubMed ID: 3144248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with Q-T prolongation (torsades de pointes).
    Schoenenberger RA; Haefeli WE; Weiss P; Ritz RF
    BMJ; 1990 May; 300(6736):1375-6. PubMed ID: 2372583
    [No Abstract]   [Full Text] [Related]  

  • 9. QT prolongation and recurrent "torsades de pointes" during erythromycin lactobionate infusion.
    Guelon D; Bedock B; Chartier C; Haberer JP
    Am J Cardiol; 1986 Sep; 58(7):666. PubMed ID: 3751946
    [No Abstract]   [Full Text] [Related]  

  • 10. Potentially fatal interaction between erythromycin and disopyramide.
    Ragosta M; Weihl AC; Rosenfeld LE
    Am J Med; 1989 Apr; 86(4):465-6. PubMed ID: 2467560
    [No Abstract]   [Full Text] [Related]  

  • 11. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible risk for cardiac arrhythmia related to intravenous erythromycin.
    Haefeli WE; Schoenenberger RA; Weiss P; Ritz R
    Intensive Care Med; 1992; 18(8):469-73. PubMed ID: 1289371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous erythromycin lactobionate in respiratory infections.
    Di Sciacca A; Durante F; Cucchiara G; Ingrassia A; Mira G; Mannone F; Di Piazza RM; Frontini A; Barbagallo Sangiorgi G
    J Int Med Res; 1987; 15(4):245-50. PubMed ID: 3653502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous erythromycin lactobionate-induced severe nausea and vomiting.
    Seifert CF; Swaney RJ; Bellanger-McCleery RA
    DICP; 1989 Jan; 23(1):40-4. PubMed ID: 2655295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous erythromycin lactobionate.
    Parsons RL; David JA; Raymond K; Stamp SM
    J Int Med Res; 1980; 8 Suppl 2():15-23. PubMed ID: 6968696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac toxicity of intravenous erythromycin lactobionate in preterm infants.
    Gouyon JB; Benoit A; Bétremieux P; Sandre D; Sgro C; Bavoux F; Beneton C; Badoual J
    Pediatr Infect Dis J; 1994 Sep; 13(9):840-1. PubMed ID: 7808866
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism.
    Nattel S; Ranger S; Talajic M; Lemery R; Roy D
    Am J Med; 1990 Aug; 89(2):235-8. PubMed ID: 2382671
    [No Abstract]   [Full Text] [Related]  

  • 18. [QT prolongation and circulatory arrest after an injection of erythromycin in a newborn infant].
    Benoit A; Bodiou C; Villain E; Bavoux F; Checoury A; Badoual J
    Arch Fr Pediatr; 1991 Jan; 48(1):39-41. PubMed ID: 2018421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of intravenous erythromycin lactobionate on theophylline clearance.
    Kimelblatt BJ; Slaughter RL
    J Allergy Clin Immunol; 1980 Apr; 65(4):313-4. PubMed ID: 7358947
    [No Abstract]   [Full Text] [Related]  

  • 20. Transient perceptive deafness due to erythromycin lactobionate.
    Mintz U; Amir J; Pinkhas J; de Vries A
    JAMA; 1973 Aug; 225(9):1122-3. PubMed ID: 4740626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.